BIO Submits Comments to CMS Regarding the CY 2015 Physician Fee Schedule Proposed Rule

August 29, 2014
Marilyn Tavenner
Centers for Medicare & Medicaid Services
Department of Health and Human Services
Room 445-G
Hubert H. Humphrey Building
200 Independence Avenue, S.W.
Washington, D.C. 20201
Re: Medicare Program; Revisions to Payment Policies Under the Physician Fee
Schedule, Clinical Laboratory Fee Schedule, Access to Identifiable Data for the
Center for Medicare and Medicaid Innovation Models & Other Revisions to
Part B for CY 2015; Proposed Rule [CMS-1612-P]
Dear Administrator Tavenner:
The Biotechnology Industry Organization (BIO) appreciates this opportunity to
comment on the Centers for Medicare & Medicaid Services’ (CMS’s) proposed rule regarding
payment policies under the physician fee schedule (PFS), clinical laboratory fee schedule,
and other revisions to Part B for calendar year (CY) 2015 (the “Proposed Rule”).1 BIO
represents more than 1,000 biotechnology companies, academic institutions, state
biotechnology centers, and related organizations in the United States. BIO members are
involved in the research and development of healthcare, agricultural, industrial, and
environmental biotechnology products.